BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26408730)

  • 1. Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients.
    Mayer B; Sander S; Paschke S; Henne-Bruns D; Link KH; Kornmann M;
    Anticancer Res; 2015 Oct; 35(10):5587-93. PubMed ID: 26408730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
    Kornmann M; Staib L; Wiegel T; Kron M; Henne-Bruns D; Link KH; Formentini A;
    Clin Colorectal Cancer; 2013 Mar; 12(1):54-61. PubMed ID: 23107590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
    O'Connell MJ; Laurie JA; Kahn M; Fitzgibbons RJ; Erlichman C; Shepherd L; Moertel CG; Kocha WI; Pazdur R; Wieand HS; Rubin J; Vukov AM; Donohue JH; Krook JE; Figueredo A
    J Clin Oncol; 1998 Jan; 16(1):295-300. PubMed ID: 9440756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
    Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha.
    Link KH; Kornmann M; Staib L; Redenbacher M; Kron M; Beger HG;
    Ann Surg; 2005 Aug; 242(2):178-87. PubMed ID: 16041207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.
    Köhne CH; Bedenne L; Carrato A; Bouché O; Popov I; Gaspà L; Valladares M; Rougier P; Gog C; Reichardt P; Wils J; Pignatti F; Biertz F
    Eur J Cancer; 2013 May; 49(8):1868-75. PubMed ID: 23571150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon-alpha in adjuvant treatment of colorectal carcinoma].
    Staib L; Link KH; Henne-Bruns D
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():142-5. PubMed ID: 12704877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
    Kornmann M; Formentini A; Ette C; Henne-Bruns D; Kron M; Sander S; Baumann W; Kreuser ED; Staib L; Link KH
    Eur J Surg Oncol; 2008 Dec; 34(12):1316-21. PubMed ID: 18313881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
    Twelves C; Scheithauer W; McKendrick J; Seitz JF; Van Hazel G; Wong A; Díaz-Rubio E; Gilberg F; Cassidy J
    Ann Oncol; 2012 May; 23(5):1190-1197. PubMed ID: 21896539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
    J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
    Arkenau HT; Bermann A; Rettig K; Strohmeyer G; Porschen R;
    Ann Oncol; 2003 Mar; 14(3):395-9. PubMed ID: 12598344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
    Hong KD; Lee SI; Moon HY
    Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
    Cheung WY; Shi Q; O'Connell M; Cassidy J; Blanke CD; Kerr DJ; Meyers J; Van Cutsem E; Alberts SR; Yothers G; Sargent DJ;
    Clin Colorectal Cancer; 2013 Sep; 12(3):179-87. PubMed ID: 23810482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
    Wilkinson NW; Yothers G; Lopa S; Costantino JP; Petrelli NJ; Wolmark N
    Ann Surg Oncol; 2010 Apr; 17(4):959-66. PubMed ID: 20082144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) with folinic acid (FA) in adjuvant therapy of colon cancer.
    Wein A; Riedel C; Brückl W; Kastl S; Reingruber B; Hohenberger W; Hahn EG
    Z Gastroenterol; 2001 Feb; 39(2):153-6. PubMed ID: 11253506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
    Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
    Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.